Clinical Trial Audit and Monitoring Services - Overview
Clinical trial audit and monitoring guarantee that the trial data is accurate, complete, verifiable, and in agreement with ethical and scientific norms. Robust clinical trial monitoring is vital to protect scientific data integrity and yield valid Regulatory data. To ensure that clinical data adhere to the protocols and international guidelines, organizations must opt for clinical trial audit and monitoring services that can manage the intricacies of bioavailability (BA) and bioequivalence (BE) studies.
Freyr’s clinical trial audit and monitoring services consist of a skilled team that showcases innovative problem-solving talents while monitoring everything from straightforward, 2-way, cross-over Bioequivalence (BE) and Bioavailability (BA) studies to large, complex, steady-state BE and BA study services. Freyr also provides independent clinical trial monitoring and auditing services for clinical and bio-analytical phases of the BE and BA studies through its highly qualified and experienced clinical study monitoring team. Our clinical experts guide clients in the preparation and review of clinical SOPs to provide continued clinical trial audit and monitoring support.
Freyr’s proactive research-based approach helps clients access the best research sites following a thorough audit of feasibility and analysis of the CRO/study site, along with high-quality monitoring throughout the trial duration, to ensure compliance with the applicable regulations and guidelines.
Clinical Trial Audit and Monitoring Services
- Clinical study monitoring services for phase I trials and bioequivalence studies
- Bio-analytical monitoring of phase I trial and bioequivalence studies
- Auditing of BE CRO/study site
- System audits of phase I-BE CRO/study site
- BA/ BE study monitoring services
- Preparation and review of clinical SOP

- In-depth clinical trial audit and monitoring knowledge perfectly integrated with IT capabilities
- Complete understanding of the complex drug development process, including new chemical entities (NCEs), generics, biologics, and biosimilars that facilitate clinical monitoring
- Vast experience in dealing with clinical trial audit imperatives across multiple therapeutic areas like oncology, cardiovascular, psychiatry, respiratory, renal, gastrointestinal, etc.
- Defined in-house processes for clinical trial monitoring to provide thorough scientific, medical, editorial, and quality control reviews before the sponsor review
